Big drug companies want Bioidentical Hormone market for themselves!

by | May 17, 2016


A green chalkboard with the message 'I LOVE YOU' written in white chalk.Action Alert!

If they’re successful, the price of bioidentical hormone replacement therapy could go through the roof. And you may not be able to get the therapy in the right form any longer.

In 2014, TherapeuticsMD, a drug company specializing in women’s healthcare, was granted two new patents for the company’s combination bioidentical-estradiol-and-progesterone drug. The patents are for the particular “recipe†of bioidentical hormones (presumably a particular ratio of estradiol to progesterone, combined with a proprietary solubilizing agent), and for the “methodâ€â€”that is, the claim that this formulation is a method of treating menopause symptoms in women.

The company is also in the midst of conducting a Phase III clinical trial on this drug, meaning that it could be very close to coming to market.
Keep in mind that this is occurring against the backdrop of the FDA’s war on natural medicine. Bioidentical hormones such as estriol, progesterone (including progesterone with estradiol), and testosterone have been nominated to the FDA’s “Demonstrably Difficult to Compound List,†and if the nominations are approved, traditional pharmacies will no longer be able to compound these hormones—which would completely eliminate competition for TherapeuticsMD’s drugs. We suspect the appearance of this drug now is no coincidence, that the drug company was encouraged by the FDA to submit it.

Even if the FDA did not ban compounded bioidentical hormones—something they have clearly wanted to do for years—this new bioidentical Big Pharma drug could still threaten patient access to affordable bioidentical hormones.

If TherapeuticsMD’s drug is approved by the FDA, without an outright ban on compounded versions, compounding pharmacies would still not be able to make that particular combination of estradiol and progesterone. Pharmacists might be allowed to adjust the ratio of hormones they use, since the principle of individualized medicine is that each medication is customized to each patient’s particular needs. But it is likely that TherapeuticsMD is seeking to hold exclusive rights on a very common combination of estradiol and progesterone, and patients requiring that ratio may have to pay what will likely be a hefty price for the drug, or go without it.

Patients would also likely have to take the medication in tablet form, because drug companies favor pills over creams, or other forms of delivery, for mass production. But integrative doctors don’t usually prescribe it in tablet form. Taking it as a sub-lingual powder gets it into the body; taking as a tablet means that it has to go through the GI tract where it may be destroyed or rendered ineffective.

If a flashy new bioidentical hormone menopause drug is approved, it is also possible that many doctors will begin prescribing that drug to their patients, rather than compounded bioidentical hormone medications, in order to avoid trouble with regulators.

An additional concern is that TherapeuticsMD, and any other company looking to get in on the action, could start snatching up more and more combinations of these hormones until they have cornered the entire market for bioidentical hormone replacement therapy—completely pushing out pharmacists from making these combinations for their patients.

We’ve also heard from pharmacists that TherapeuticsMD is attempting to form partnerships with compounding pharmacies to push their new drug, allowing the company to piggyback on the relationships pharmacists already have with both patients and doctors. Pharmacists might feel forced into such relationships by regulators who clearly favor the drug companies.

It is critical to maintain consumer access to affordable bioidentical hormones. We’ve seen how the FDA’s actions on compounded medications have caused the price of vitamin B12 shots to skyrocket and for the best form of the shot to be hard to get. It is imperative to prevent this from happening to bioidentical hormones.

Action Alert! Write to the FDA and tell them that they must preserve consumer access to bioidentical hormones. Please send your message immediately.
Source: Alliance for Natural Health, USA, May 17, 2016


Send Your Message!

Ivermectin + Mebendazole taken together produce remarkably Positive Clinical Cancer Benefits in 84.4% of Patients.

The largest real-world human analysis to date evaluating ivermectin and mebendazole in cancer patients has just been published—and the results represent one of the most compelling clinical signals ever documented for repurposed anti-parasitic therapies in oncology.

This groundbreaking analysis was made possible through a unique collaboration between The Wellness Company, the McCullough Foundation, and the Chairman of the President’s Cancer Panel (Dr. Harvey Risch)—uniting real-world clinical data, frontline medical experience, and high-level epidemiologic expertise to deliver urgently needed insights in oncology.

This was a real-world prospective clinical program evaluation of 197 cancer patients, with 122 completing a follow-up survey at about six months (61.9% response rate).

Cancer patients were prescribed compounded ivermectin–mebendazole, with each capsule containing 25 mg ivermectin and 250 mg mebendazole—most commonly taken at 1–2 capsules per day.

The cohort represented a clinically relevant population, including a wide variety cancer types, with 37.1% of patients reporting actively progressing disease at baseline and many having already undergone chemotherapy, radiation, and surgery.

At six months, 84.4% of cancer patients reported clinical benefit (Clinical Benefit Ratio: 84.4% [95% CI: 77.0–89.8%]):

✅ 32.8% reported NO evidence of cancer (95% CI: 25.1–41.5%)
✅ 15.6% reported tumor regression (95% CI: 10.2–23.0%)
✅ 36.1% reported stable disease (95% CI: 28.1–44.9%)

Treatment adherence was high, with 86.9% completing the full protocol and 66.4% remaining on therapy at six months.

The regimen was well tolerated, with 25.4% reporting side effects, primarily mild and gastrointestinal, and over 93% continuing treatment despite these events.

Patients were treated in real-world conditions alongside concurrent therapies, including chemotherapy (27.9%), radiation (21.3%), surgery (19.7%), supplements (49.2%), and dietary modification (37.7%), supporting use as an adjunctive approach.

Together, these findings represent a large, internally consistent real-world clinical signal that supports URGENT further investigation of ivermectin and mebendazole as low-toxicity, adjunctive cancer therapies.

Given the strength of the signal observed here, advancing this line of investigation is no longer optional—it is necessary.

This is NOT the end. We will continue advancing this work with larger datasets to further define and validate the role of anti-parasitics in cancer outcomes.

The manuscript is now available as a preprint on the Zenodo research repository, operated by the European Organization for Nuclear Research, while undergoing peer review at leading oncology journals: “Real-World Clinical Outcomes of Ivermectin and Mebendazole in Cancer Patients: Results from a Prospective Observational Cohort.”

Bar chart showing distribution of common cancer types with breast cancer most prevalent.
Infographic on disease status and median duration since diagnosis.

Receive Our Newsletter

12 + 1 =

jQuery( document ).ready(function( $ ) { // $( "div" ).hide(); });